GLP-1 / GIP dual receptor agonist studied in metabolic models.
For research use only. Not for human or veterinary use. No claims of safety, efficacy or therapeutic benefit.
Dual GLP-1/GIP receptor activity; body-weight and metabolic outcomes. Phase 3 trials reported substantial weight reduction in selected adults with obesity, including a separate trial in type 2 diabetes; gastrointestinal adverse events are relevant.
Clinical findings apply to the studied formulation, population and indication. They do not establish equivalence, safety or therapeutic efficacy of this research product.
PMID: 35658024, 37385275
Contact the Avitus team to confirm available presentations, product specifications and pricing for your research requirements.